Se Chang Kwon

This inventor holds 90 USPTO granted patents and 28 published patent applications, plus 40 CIPO patents and 62 EPO patents, primarily in Protein Conjugates (CPC class C07K2319-30). Top assignees: Hanmi Pharm. Co., Ltd., Hanmi Science Co., Ltd., Hanmi Holdings Co., Ltd.. Active years: 2009-2025.

USPTO Granted Patents = 90 (Patent Applications = 28)

% Patents Active = 83.3

CIPO Patents = 40 (Patent Applications = 14)

EPO Patents = 62 (Patent Applications = 90)

Average Co-Inventor Count = 5.7

ph-index = 10

Forward Citations = 452(Granted Patents)

Forward Citations (Not Self Cited) = 269(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Gwangjin-gu, KR (2010 - 2014)
Gangnam-gu, KR (2018)
Hwaseong-si, KR (2018 - 2023)
Seoul, KR (2009 - 2024)
Gyeonggi-do, KR (2019 - 2024)

Company Filing History:

44 out of 148

Hanmi Pharm. Co., Ltd.

patents

41 out of 63

Hanmi Science Co., Ltd.

patents

3 out of 12

Hanmi Holdings Co., Ltd.

patents

4. 1 out of 4

Avicore Biotechnology Institute Inc.

patents

5. 1 out of 13

Beijing Hanmi Pharmaceutical Co., Ltd.

Seoul National University

patents

8. 1 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Protein Complex

Immunoglobulin Fragment

Long-Acting Insulin

Glucagon Derivatives

Oxyntomodulin

Insulin Analogs

Polypeptide Conjugate

Therapeutic Enzymes

Liquid Formulation

Diabetes Treatment

Biologically Active Polypeptide

Drug Carrier

90 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12508298 - PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE (2025-12-30),

2. 12274750 - Lyophilized formulation of long-acting human growth hormone immunoglobulin conjugate (2025-04-14),

3. 12139455 - Polyethylene glycol derivative and use thereof (2024-11-12),

4. 12018060 - Glucagon derivatives (2024-06-25),

5. 11872283 - Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof (2024-01-16),

6. 11752216 - Insulin analog complex with reduced affinity for insulin receptor and use thereof (2023-09-12),

7. 11603346 - Polyethylene glycol derivative and use thereof (2023-03-14),

8. 11434271 - Method for preparing physiologically active polypeptide complex (2022-09-06),

9. 11389508 - Protein complex by use of a specific site of an immunoglobulin fragment for linkage (2022-07-19),

10. 11332508 - Triple glucagon/GLP-1/GIP receptor agonist (2022-05-17),

11. 11254724 - Glucagon derivatives (2022-02-22),

12. 11207383 - Protein complex by use of a specific site of an immunoglobulin fragment for linkage (2021-12-28),

13. 11168109 - Process for preparation of physiologically active polypeptide complex (2021-11-09),

14. 11135271 - Glucagon derivatives with improved stability (2021-10-05),

15. 11123436 - Method of preparing physiologically active polypeptide conjugate (2021-09-21),

As a website focusing on innovations and inventors, I understand your interest in learning about inventor Se Chang Kwon from Seoul, KR. Let's delve into his remarkable journey and contributions to the field of inventions.

Title: Unveiling the Inventive Work of Se Chang Kwon from Seoul

Introduction: Se Chang Kwon, a talented inventor hailing from Seoul, South Korea, has made significant strides in the realm of patents with a portfolio boasting 86 innovations.

Latest Patents: Among his latest patents is a groundbreaking invention involving a conjugate comprising oxyntomodulin and an immunoglobulin fragment. This innovation demonstrates promising capabilities in the prevention and treatment of obesity, offering a safe and effective solution for patients. Another notable patent is an insulin analog complex designed to reduce the affinity for insulin receptors, showcasing his prowess in the medical field.

Career Highlights: Se Chang Kwon has contributed his expertise to esteemed companies such as Hanmi Science Co., Ltd. and Hanmi Pharm. Co., Ltd., where his innovative spirit has flourished. His dedication to pioneering research and development has led to transformative inventions that have the potential to positively impact healthcare practices.

Collaborations: Throughout his career, Se Chang Kwon has collaborated with accomplished individuals such as Sung Youb Jung and Sung Min Bae, fostering a dynamic environment for creativity and innovation. These partnerships have enriched his inventive journey, enabling the exchange of ideas and the realization of groundbreaking concepts.

Conclusion: In conclusion, Se Chang Kwon's inventive prowess and commitment to excellence have solidified his position as a trailblazing inventor in the realm of patents. His innovative solutions hold great promise for addressing critical healthcare challenges and improving the quality of life for individuals worldwide.